DrugPatentWatch Database Preview
ELIQUIS Drug Profile
Which patents cover Eliquis, and when can generic versions of Eliquis launch?
Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and thirty-nine patent family members in forty countries.
The generic ingredient in ELIQUIS is apixaban. There are twenty-eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the apixaban profile page.
Summary for ELIQUIS
| International Patents: | 139 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 95 |
| Clinical Trials: | 46 |
| Patent Applications: | 833 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ELIQUIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELIQUIS |
| DailyMed Link: | ELIQUIS at DailyMed |
Generic Entry Opportunity Date for ELIQUIS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ELIQUIS
| Drug Class | Factor Xa Inhibitor |
| Mechanism of Action | Factor Xa Inhibitors |
Synonyms for ELIQUIS
| 1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide |
| 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidyl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-car |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide?BMS-562247; BMS-562247-01 |
| 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)- |
| 1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]- |
| 2p16 |
| 3Z9Y7UWC1J |
| 4,5,6,7-TETRAHYDRO-1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXO-1-PIPERIDINYL)PHENYL]-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE |
| 503612-47-3 |
| 612A473 |
| AB0007933 |
| AB01565766_02 |
| AB1008435 |
| ABP000333 |
| AC-26301 |
| AJ-59962 |
| AK161862 |
| AKOS005146204 |
| AN-429 |
| AOB87769 |
| Apixaban |
| Apixaban - Adooq Bioscience |
| Apixaban (BMS 562247-01) |
| Apixaban (JAN/USAN/INN) |
| Apixaban [USAN] |
| Apixaban BMS-562247-01 |
| Apixaban,BMS-562247-01 |
| Apixaban;503612-47-3 |
| Apixaban(BMS-562247-01) |
| Apixaban/BMS562247-01/Apixaban |
| apixabanum |
| Apixabin |
| AX8161411 |
| BC654125 |
| BCP9000310 |
| BCPP000396 |
| BDBM19023 |
| BMS 562247 |
| BMS 562247-01 |
| BMS-562247 |
| BMS-562247-01 |
| BMS-562247-01, Apixaban |
| BMS562247-01 |
| CA0186 |
| CCG-229675 |
| CHEBI:72296 |
| CHEMBL231779 |
| CS-0401 |
| D03213 |
| D0I5HF |
| DB06605 |
| DTXSID80436500 |
| Eliquis (TN) |
| EX-A048 |
| FT-0686944 |
| GG2 |
| GTPL6390 |
| HE069298 |
| HE346199 |
| HMS3655O07 |
| HY-50667 |
| I14-11577 |
| J-200194 |
| KB-47429 |
| KS-0000075V |
| ME-0152 |
| MFCD11977295 |
| MLS006010026 |
| MolPort-006-170-153 |
| NCGC00346555-01 |
| PB10976 |
| PYR431 |
| Q-4456 |
| QC-8191 |
| QNZCBYKSOIHPEH-UHFFFAOYSA-N |
| ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide |
| RP18047 |
| s1593 |
| SC-49755 |
| SCHEMBL118023 |
| SMR004676529 |
| ST24045978 |
| UNII-3Z9Y7UWC1J |
| X1060 |
| ZINC11677837 |
US Patents and Regulatory Information for ELIQUIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-002 | Dec 28, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ELIQUIS
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for ELIQUIS
Supplementary Protection Certificates for ELIQUIS
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2011012,C1427415 | Lithuania | ➤ Sign Up | PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518 |
| 2011 00028 | Denmark | ➤ Sign Up | |
| 888 | Luxembourg | ➤ Sign Up | 91888, EXPIRES: 20260518 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
